/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Valued at $10.7 billion by market cap, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The Cambridge, Massachusetts-based company is best known for its COVID-19 vaccine (mRNA-1273, branded as Spikevax), which was one of the first mRNA vaccines authorized for emergency use globally.
The healthcare major is expected to announce its third-quarter results on Thursday, Nov. 6. Ahead of the event, analysts expect Moderna to deliver a loss of $2.03 per share, down significantly from the profit of $0.03 per share reported in the year-ago quarter. On a positive note, the company has surpassed the Street’s bottom-line estimates in each of the past four quarters.